Pituitary adenoma: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
No edit summary
Line 66: Line 66:
==References==
==References==
# {{note|thyrotrophic}}{{note_label|thyrotrophic|1|a}} Chanson, Philippe; Weintraub, Bruce D.; and Harris, Alan G. (1993)  [http://www.annals.org/cgi/content/full/119/3/236 Octreotide Therapy for Thyroid-Stimulating Hormone-Secreting Pituitary Adenomata]. ''Annals of Internal Medicine'' '''119''' (3), 236-240.
# {{note|thyrotrophic}}{{note_label|thyrotrophic|1|a}} Chanson, Philippe; Weintraub, Bruce D.; and Harris, Alan G. (1993)  [http://www.annals.org/cgi/content/full/119/3/236 Octreotide Therapy for Thyroid-Stimulating Hormone-Secreting Pituitary Adenomata]. ''Annals of Internal Medicine'' '''119''' (3), 236-240.
==See Also==
* [[Adult brain tumors]]


==External links==  
==External links==  

Revision as of 03:02, 18 January 2009

Pituitary adenoma
ICD-10 D35.2
ICD-9 237.0
ICD-O: Template:ICDO
MedlinePlus 000704
eMedicine neuro/312 
MeSH D010911

WikiDoc Resources for Pituitary adenoma

Articles

Most recent articles on Pituitary adenoma

Most cited articles on Pituitary adenoma

Review articles on Pituitary adenoma

Articles on Pituitary adenoma in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Pituitary adenoma

Images of Pituitary adenoma

Photos of Pituitary adenoma

Podcasts & MP3s on Pituitary adenoma

Videos on Pituitary adenoma

Evidence Based Medicine

Cochrane Collaboration on Pituitary adenoma

Bandolier on Pituitary adenoma

TRIP on Pituitary adenoma

Clinical Trials

Ongoing Trials on Pituitary adenoma at Clinical Trials.gov

Trial results on Pituitary adenoma

Clinical Trials on Pituitary adenoma at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Pituitary adenoma

NICE Guidance on Pituitary adenoma

NHS PRODIGY Guidance

FDA on Pituitary adenoma

CDC on Pituitary adenoma

Books

Books on Pituitary adenoma

News

Pituitary adenoma in the news

Be alerted to news on Pituitary adenoma

News trends on Pituitary adenoma

Commentary

Blogs on Pituitary adenoma

Definitions

Definitions of Pituitary adenoma

Patient Resources / Community

Patient resources on Pituitary adenoma

Discussion groups on Pituitary adenoma

Patient Handouts on Pituitary adenoma

Directions to Hospitals Treating Pituitary adenoma

Risk calculators and risk factors for Pituitary adenoma

Healthcare Provider Resources

Symptoms of Pituitary adenoma

Causes & Risk Factors for Pituitary adenoma

Diagnostic studies for Pituitary adenoma

Treatment of Pituitary adenoma

Continuing Medical Education (CME)

CME Programs on Pituitary adenoma

International

Pituitary adenoma en Espanol

Pituitary adenoma en Francais

Business

Pituitary adenoma in the Marketplace

Patents on Pituitary adenoma

Experimental / Informatics

List of terms related to Pituitary adenoma

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Pituitary adenomas are tumors that occur in the pituitary gland, and account for about 10% of intracranial neoplasms. They often remain undiagnosed, and small pituitary tumors are found in 6 to 24 percent of adults at autopsy.

Pituitary adenomas arise within the anterior lobe (adenohypophysis) of the gland . Tumors less than 1 cm are called micro adenomas. Clinical symptoms depend on whether the tumor is secreting or nonsecreting. Nonsecreting adenomas grow and compress adjacent structures, most commonly causing a bitemporal hemianopsia due to chiasmatic compression. Lateral extension into the cavernous sinuses can result in cranial nerve palsies.

Types

Pituitary tumors were, historically, classed as basophilic, acidophilic, or chromophobic on the basis of whether or not they took up the stains hematoxylin and eosin. This classification has fallen into disuse, in favor of a classification based on what type of hormone is secreted by the tumor (though tumors which do not secrete any active hormone ("non-functioning tumors") are still sometimes called "chromophobic").

At present, classification of pituitary tumors is based on plasma hormone levels or immunohistochemical staining:

Type of adenoma Secretion Staining Pathology
corticotrophic adenomas secrete adrenocorticotropic hormone (ACTH) and pro-opiomelanocortin (POMC) basophilic Cushing's disease
somatotrophic adenomas secrete growth hormone (GH) acidophilic acromegaly (gigantism)
thyrotrophic adenomas (rare) secrete thyroid-stimulating hormone (TSH) basophilic occasionally hyperthyroidism[3], usually doesn't cause symptoms
gonadotrophic adenomas secrete luteinizing hormone (LH), follicle-stimulating hormone (FSH) and their subunits basophilic usually doesn't cause symptoms
lactrotrophic adenomas or prolactinomas (most common) secrete prolactin acidophilic galactorrhea, hypogonadism, amenorrhea, infertility, and impotence
null cell adenomas do not secrete hormones may stain positive for synaptophysin

Diagnosis

The diagnosis is generally entertained either on the basis of visual difficulties arising from the compression of the optic nerve by the tumor, or on the basis of manifestations of excess hormone secretion: the specifics depend on the type of hormone. The specific area of the visual pathway at which compression by these tumours occurs is at the optic chiasma.

The anatomy of this structure causes pressure on it to produce a defect in the temporal visual field on both sides, a condition called bitemporal hemianopia.

Tumors which cause visual difficulty are likely to be macroadenomata greater than 10 mm in diameter; tumors less than 10 mm are microadenomata.

Some tumors secrete more than one hormone, the most common combination being GH and prolactin.

Prolactinomas are frequently diagnosed during pregnancy, when the hormone progesterone increases the tumor's growth rate. Headaches may be present. The diagnosis is confirmed by testing hormone levels, and by radiographic imaging of the pituitary (for example, by CT scan or MRI).

Treatment

Treatment options depend on the type of tumor and on its size:

  • Prolactinomas are most often treated with bromocriptine or more recently, cabergoline which, unlike bromocriptine, decreases tumor size as well as alleviates symptoms, both dopamine agonists, and followed by serial imaging to detect any increase in size. Treatment where the tumor is large can be with radiation therapy or surgery, and patients generally respond well. Efforts have been made to use a progesterone antagonist for the treatment of prolactinomas, but so far have not proved successful.
  • Thyrotrophic adenomas respond to octreotide, a long-acting somatostatin analog, in many but not all cases according to a review of the medical literature. Unlike prolactinomas, thyrotrophic adenomas characteristically respond poorly to dopamine agonist treatment.Template:Ref label

References

  1. ^ Template:Note label Chanson, Philippe; Weintraub, Bruce D.; and Harris, Alan G. (1993) Octreotide Therapy for Thyroid-Stimulating Hormone-Secreting Pituitary Adenomata. Annals of Internal Medicine 119 (3), 236-240.

See Also

External links


Template:SIB

cs:Adenom hypofýzy nl:Hypofysetumor sk:Adenóm hypofýzy sv:Hypofystumör


Template:WikiDoc Sources